Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.69 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.60 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.60 |
| ▸ | DNPH1 | O43598 | 2/20 | 0.60 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.60 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.60 |
| ▸ | LDHA | P00338 | 1/20 | 0.60 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.60 |
| ▸ | FBP1 | P09467 | 1/20 | 0.60 |
| ▸ | SRC | P12931 | 1/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.60 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.60 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.60 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.60 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytarabine 5'-Phosphate SCHEMBL29424346 | 1.00 | P2RX3 (0.69) | P2RX3TAS1R3TAS1R1P2RY2DNPH1 | |
| Cytarabine 5'-Phosphate SCHEMBL29359440 | 0.94 | P2RY2 (0.70) | P2RX3P2RY2IMPDH2IMPDH1 | |
| SCHEMBL29452474 | 0.93 | P2RX3 (0.65) | P2RX3TAS1R3TAS1R1P2RY2DNPH1 | |
| Cytarabine 5'-Phosphate SCHEMBL29390918 | 0.92 | P2RX3 (0.59) | P2RX3TAS1R3TAS1R1P2RY2DNPH1 | |
| SCHEMBL24160912 | 0.89 | P2RX3 (0.85) | P2RX3TAS1R3TAS1R1P2RY2DNPH1 | |
| SCHEMBL12931223 | 0.89 | P2RX3 (0.85) | P2RX3TAS1R3TAS1R1P2RY2DNPH1 | |
| SCHEMBL12727824 | 0.89 | P2RX3 (0.85) | P2RX3TAS1R3TAS1R1P2RY2DNPH1 | |
| SCHEMBL184240 | 0.89 | P2RX3 (0.85) | P2RX3TAS1R3TAS1R1P2RY2DNPH1 | |
| SCHEMBL18258283 | 0.89 | P2RX3 (0.85) | P2RX3TAS1R3TAS1R1P2RY2DNPH1 | |
| SCHEMBL24377014 | 0.89 | P2RX3 (0.85) | P2RX3TAS1R3TAS1R1P2RY2DNPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 585 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-05-12 | — | — | US | claimed |
| US-12622956-B2 | Methods and vaccines for inducing immune responses to multiple different MHC molecules | Mayo Foundation for Medical Education and Research; (MN) | 2026-05-12 | — | — | US | claimed |
| US-20260115281-A1 | TRITERPENE SAPONIN ANALOGUES | ADJUVANCE TECH INC (US) | 2026-04-30 | — | — | US | claimed |
| US-12594291-B2 | Intratumoral alpha-emitter radiation and activation of cytoplasmatic sensors for intracellular pathogen | ALPHA TAU MEDICAL LTD (IL) | 2026-04-07 | — | — | US | claimed |
| US-12569554-B2 | Triterpene saponin analogues | ADJUVANCE TECHNOLOGIES, INC. (US) | 2026-03-10 | — | — | US | claimed |
| US-20260041758-A1 | IMMUNIZATION STRATEGIES TO MORE NATURALLY GUIDE THE MATURATION OF ANTIBODIES AGAINST HUMAN IMMMUNODEFICIENCY VIRUS (HIV) IN HIV-INFECTED SUBJECTS | FRED HUTCHINSON CANCER CENTER (US) | 2026-02-12 | — | — | US | claimed |
| US-12433940-B2 | Silicified cell replicas, methods of making, and methods of using | UNM RAINFOREST INNOVATIONS (US) | 2025-10-07 | — | — | US | claimed |
| EP-3873598-B1 | INTRATUMORAL ALPHA-EMITTER RADIATION AND ACTIVATION OF CYTOPLASMATIC SENSORS FOR INTRACELLULAR PATHOGEN | ALPHA TAU MEDICAL LTD (IL) | 2025-07-02 | — | — | EP | claimed |
| WO-2025137325-A1 | IMMUNIZATION SCHEDULES TO ELICIT BROADLY-NEUTRALIZING ANTIBODIES AGAINST HUMAN IMMMUNODEFICIENCY VIRUS (HIV) | FRED HUTCHINSON CANCER CENTER (US) | 2025-06-26 | — | — | WO | claimed |
| CN-120137897-A | PBMC and DC loaded tumor cell antigen peptide immune co-culture method and application | 创芯国际生物科技(广州)有限公司 | 2025-06-13 | — | — | CN | claimed |
| CN-115029311-A | Anucleated cell for targeted macrophage delivery and preparation method and application thereof | 中国药科大学 | 2022-09-09 | — | — | CN | claimed |
| US-20220267734-A1 | HETEROGENEOUS STEM CELL POPULATION, PREPARATION METHOD THEREFOR AND USE THEREOF | INSTITUTE OF BASIC MEDICAL SCIENCES, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2022-08-25 | — | — | US | claimed |
| EP-4041295-A1 | MULTI-DOMAIN PROTEIN VACCINE | Fritsch, Edward (US) | 2022-08-17 | — | — | EP | claimed |
| CN-114681612-A | Bladder perfusion pharmaceutical composition and preparation method and application thereof | 苏州百迈生物医药有限公司 | 2022-07-01 | — | — | CN | claimed |
| US-20220175926-A1 | TARGETED SYNERGISTIC CANCER IMMUNOTHERAPY | BRIGHAM & WOMENS HOSPITAL INC (US) | 2022-06-09 | — | — | US | claimed |
| US-20220175814-A1 | IMMUNOTHERAPY FOR THE TREATMENT OF CANCER | TARGIMMUNE THERAPEUTICS AG (CH) | 2022-06-09 | — | — | US | claimed |
| EP-3999110-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS | The Regents of The University of Michigan (US) | 2022-05-25 | — | — | EP | claimed |
| US-20220125835-A1 | SILICIFIED IMMUNOGENIC CELLS, METHODS OF MAKING, AND METHODS OF USING | UNM RAINFOREST INNOVATIONS | 2022-04-28 | — | — | US | claimed |
| US-20220072023-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-10 | — | — | US | claimed |
| US-20220040291-A1 | HCoV VACCINE FOR IMPROVING IMMUNITY AGAINST SARS-COV-2 INFECTION | MOORE TIMOTHY S (US) | 2022-02-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072023-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | MYD88, STING1, TLR3 | P2RX3 260/4885TAS1R3 409/4885TAS1R1 385/4885 |
| US-12569554-B2 | Triterpene saponin analogues | TLR4, TLR7, TLR8 | P2RX3 272/4885TAS1R3 2272/4885TAS1R1 3637/4885 |
| US-20260115281-A1 | TRITERPENE SAPONIN ANALOGUES | NR1H2, NR1H3, LSS | P2RX3 2531/4885TAS1R3 3070/4885TAS1R1 2537/4885 |
| US-20220175814-A1 | IMMUNOTHERAPY FOR THE TREATMENT OF CANCER | TLR3, CD274, PDCD1 | P2RX3 3786/4885TAS1R3 1487/4885TAS1R1 1696/4885 |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | STING1, CGAS, TLR3 | P2RX3 57/4885TAS1R3 275/4885TAS1R1 525/4885 |
| US-12594291-B2 | Intratumoral alpha-emitter radiation and activation of cytoplasmatic sensors for intracellular pathogen | STING1, IFNAR1, IFNG | P2RX3 2419/4885TAS1R3 1134/4885TAS1R1 763/4885 |
| US-12622956-B2 | Methods and vaccines for inducing immune responses to multiple different MHC molecules | MICA, MUC1, MYD88 | P2RX3 1298/4885TAS1R3 691/4885TAS1R1 1601/4885 |
| US-20260041758-A1 | IMMUNIZATION STRATEGIES TO MORE NATURALLY GUIDE THE MATURATION OF ANTIBODIES AGAINST HUMAN IMMMUNODEFICIENCY VIRUS (HIV) IN HIV-INFECTED SUBJECTS | CD4, IGSF11, ICOS | P2RX3 1345/4885TAS1R3 1167/4885TAS1R1 1868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.